SYS6023 not checked

CSPC

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
2 active
2 in total
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“SYS6023 is a novel antibody-drug conjugate (ADC) targeting HER3, administered via intravenous infusion.”In the company’s words, NCT07597629 on ClinicalTrials.gov
Tested for
Advanced Breast Cancer, Advanced Solid Tumor
Main trialPhase 2
“This is an open-label, multicenter Phase II clinical study conducted in subjects with advanced breast cancer.”In the company’s words, NCT07597629 on ClinicalTrials.gov

Other drugs for Advanced Breast Cancer

All 396 drugs for Advanced Breast Cancer

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 2Recruiting 30 Nov 2027 A Clinical Study of SYS6023 Combination Therapy for Advanced Breast Cancer
Phase 1Recruiting 31 Oct 2026 A Clinical Study of SYS6023 in Patients With Advanced Solid Tumors
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow SYS6023

Following is part of Solo: you see every change to SYS6023 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in